BG Medicine Inc. has received approval from the U.S. Food and Drug Administration for its cardiac test, Galectin-3, which is designed to measure galectin-3 blood levels.
The Waltham-based company is aiming for commercialization of Galectin-3 within 45 days of FDA clearance and is working with LabCorp to achieve that. BG Medicine is also working with Abbott Laboratories, Alere Inc. and bioMérieux SA to make automated versions of the Galectin-3 test for platforms related to the three companies.
SOURCE